Founded by physician-scientists nearly 30 years ago, our science-driven approach has resulted in five FDA-approved medicines and numerous product candidates in a range of diseases, including cancer, rheumatoid arthritis, asthma, pain and infectious diseases.
In addition to our medicines, our innovations include the VelociSuite® technologies, world-class manufacturing operations, one of the largest human sequencing efforts in the world and rapid response technologies being used for global good.
$388.49 21.87 (5.97)%
Market Cap 40.47B
04/28/17 4:00 PM ET | Minimum 20 minutes delay.
Stock information provided by eSignal.
Regeneron Pharmaceuticals Q1 2017 Earnings Conference Call
May 4, 2017 | 8:30 AM
2017 Annual Meeting of Shareholders
Jun 9, 2017 | 10:30 AM ET